|CHAPEL HILL, N.C., May 01, 2007 (BUSINESS WIRE) -- POZEN Inc. (NASDAQ: POZN) announced today that John R. Plachetka,
Pharm.D., the company's chairman, president and chief executive
officer, will present at the Robert W. Baird & Co. 2007 Growth Stock
Conference on Thursday, May 10, 2007 at 7:45 a.m. (CT) at the Four
Seasons Hotel in Chicago. Dr. Plachetka's presentation will be webcast
and archived on POZEN's home page at www.pozen.com.
POZEN is a pharmaceutical company committed to developing
therapeutic advancements for diseases with unmet medical needs where
it can improve efficacy, safety, and/or patient convenience. POZEN's
efforts are focused primarily on the development of pharmaceutical
products for the treatment of acute and chronic pain and other
pain-related conditions. POZEN has development and commercialization
alliances with GlaxoSmithKline for the proposed product candidate
Trexima(TM) combining sumatriptan, formulated with RT Technology(TM),
and naproxen sodium in a single tablet for the acute treatment of
migraine, which is currently under review by the United States Food
and Drug Administration, and with AstraZeneca for proprietary fixed
dose combinations of naproxen with the proton pump inhibitor
esomeprazole magnesium in a single tablet for conditions such as
osteoarthritis and rheumatoid arthritis in patients who are at risk
for developing NSAID-associated gastric ulcers. The company's common
stock is traded on The Nasdaq Stock Market under the symbol "POZN".
For detailed company information, including copies of this and other
press releases, see POZEN's website: www.pozen.com.
SOURCE: POZEN Inc.
Bill Hodges, 919-913-1030
Chief Financial Officer
Fran Barsky, 919-913-1044
Director, Investor Relations